Cover Image
市場調查報告書

Smoothened Homolog:開發中產品分析

Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 365789
出版日期 內容資訊 英文 72 Pages
訂單完成後即時交付
價格
Back to Top
Smoothened Homolog:開發中產品分析 Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017
出版日期: 2017年07月25日 內容資訊: 英文 72 Pages
簡介

本報告提供以Smoothened Homolog為標的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Smoothened Homolog 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 開發中的產品:各企業
  • 開發中的產品:各大學/機關

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • BeiGene, Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Ignyta, Inc.
  • IMPACT Therapeutics Inc
  • Mayne Pharma Group Limited
  • Pfizer Inc.
  • Redx Pharma Plc
  • Sun Pharma Advanced Research Company Ltd

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息及新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC0953TDB

Summary:

Smoothened Homolog (Protein Gx or SMO) - Smoothened homolog (SMO) is a G protein-coupled receptor that probably associates with the patched protein (PTCH) to transduce the hedgehog's proteins signal. Binding of sonic hedgehog (SHH) to its receptor is thought to prevent normal inhibition by patched of smoothened (SMO). It is required for the accumulation of KIF7 and GLI3 in the cilia.

Smoothened Homolog (Protein Gx or SMO) pipeline Target constitutes close to 11 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II and Preclinical stages are 6 and 3 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Oncology, Genetic Disorders, Gastrointestinal, Respiratory and Undisclosed which include indications Basal Cell Carcinoma (Basal Cell Epithelioma), Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma Of The Gastroesophageal Junction, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Gorlin Syndrome (Basal Cell Nevus Syndrome), Medulloblastoma, Cirrhosis, Esophageal Cancer, Idiopathic Pulmonary Fibrosis, Leukemias, Meningioma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hepatocellular Carcinoma (HCC), Myelodysplastic Syndrome, Peritoneal Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma and Small-Cell Lung Cancer.

The latest report Smoothened Homolog (Protein Gx or SMO) - Pipeline Review, H2 2017, outlays comprehensive information on the Smoothened Homolog (Protein Gx or SMO) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Smoothened Homolog (Protein Gx or SMO)
  • The report reviews Smoothened Homolog (Protein Gx or SMO) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Smoothened Homolog (Protein Gx or SMO) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Smoothened Homolog (Protein Gx or SMO) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Smoothened Homolog (Protein Gx or SMO) targeted therapeutics

Reasons to buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Smoothened Homolog (Protein Gx or SMO)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Smoothened Homolog (Protein Gx or SMO) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Smoothened Homolog (Protein Gx or SMO) - Overview
    • Smoothened Homolog (Protein Gx or SMO) - Therapeutics Development
    • Products under Development by Stage of Development
    • Products under Development by Therapy Area
    • Products under Development by Indication
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Smoothened Homolog (Protein Gx or SMO) - Therapeutics Assessment
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Smoothened Homolog (Protein Gx or SMO) - Companies Involved in Therapeutics Development
    • BeiGene Ltd
    • F. Hoffmann-La Roche Ltd
    • Ignyta Inc
    • IMPACT Therapeutics Inc
    • Mayne Pharma Group Ltd
    • Pfizer Inc
    • Redx Pharma Plc
    • Sun Pharma Advanced Research Company Ltd
  • Smoothened Homolog (Protein Gx or SMO) - Drug Profiles
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-5471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patidegib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • glasdegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GSA-10 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • IMP-5471 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • itraconazole - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • patidegib hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RDX-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Smoothened (Smo) Receptor for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Smoothened Homolog for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sonidegib phosphate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • taladegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • vismodegib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Smoothened Homolog (Protein Gx or SMO) - Dormant Products
  • Smoothened Homolog (Protein Gx or SMO) - Discontinued Products
  • Smoothened Homolog (Protein Gx or SMO) - Product Development Milestones
    • Featured News & Press Releases
      • May 30, 2017: HedgePath Pharmaceuticals Announces Granting of Type-C Meeting Request by FDA and Provides Positive Clinical Trial Update
      • Dec 08, 2016: PellePharm Launches with Financing from BridgeBio Pharma to Develop Topical Therapy for Basal Cell Carcinomas and Gorlin Syndrome
      • Dec 03, 2016: New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
      • Nov 28, 2016: Curis Announces Full Approval of Roche's Erivedge in the European Union
      • Oct 20, 2016: HedgePath Pharmaceuticals Announces Further Positive Interim Data in its Phase II(b) Cancer Trial
      • Aug 03, 2016: HedgePath Pharmaceuticals Announces Positive Interim Data in its Phase II(b) Cancer Trial
      • Jun 02, 2016: Curis Announces Presentations Related to Erivedge at 2016 ASCO Annual Meeting
      • Jun 02, 2016: FDA Grants Orphan Drug Designation to SUBA-Itraconazole for Treatment of Patients with BCCNS
      • Sep 29, 2015: HedgePath Pharmaceuticals Announces Commencement of Patient Treatment in its Phase II(b) Clinical Trial
      • Aug 21, 2015: HedgePath Pharmaceuticals Launches Clinical Trial for its Proposed Cancer Treatment
      • Aug 20, 2015: Novartis drug Odomzo gains EU approval for locally advanced basal cell carcinoma, providing new non-invasive therapy for patients
      • Jul 24, 2015: FDA approves Novartis drug Odomzo (sonidegib) for locally advanced basal cell carcinoma (laBCC), a form of skin cancer
      • May 20, 2015: Curis Announces Presentations of Erivedge Clinical Data at 2015 ASCO Annual Meeting
      • May 18, 2015: New Equity Investment In Hedgepath Pharmaceuticals Ahead Of Commencing Phase IIB Trial With Suba-Itraconazole In Skin Cancer
      • Mar 09, 2015: Skin tumors develop specific mutations to resist drug, researchers say
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Indications, H2 2017
  • Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017
  • Number of Products under Investigation by Universities/Institutes, H2 2017
  • Products under Investigation by Universities/Institutes, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Pipeline by BeiGene Ltd, H2 2017
  • Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
  • Pipeline by Ignyta Inc, H2 2017
  • Pipeline by IMPACT Therapeutics Inc, H2 2017
  • Pipeline by Mayne Pharma Group Ltd, H2 2017
  • Pipeline by Pfizer Inc, H2 2017
  • Pipeline by Redx Pharma Plc, H2 2017
  • Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017
  • Dormant Products, H2 2017
  • Dormant Products, H2 2017 (Contd..1), H2 2017
  • Dormant Products, H2 2017 (Contd..2), H2 2017
  • Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development by Stage of Development, H2 2017
  • Number of Products under Development by Therapy Areas, H2 2017
  • Number of Products under Development by Top 10 Indications, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
Back to Top